Oragenics partners with Avance Clinical for Phase II concussion trial of ONP-002 in Australia

ORAGENICS INC

Phase II trial to evaluate ONP-002 for mild traumatic brain injury (concussion) delivered intranasally.
Phase I trial completed under Avance Clinical showed ONP-002 safe and well-tolerated.
Avance Clinical, a CRO with 20+ years experience, will manage the trial in Australia.
Oragenics President cites confident execution; CMO highlights Australia's head injury expertise.
Worldwide annual concussions estimated at 69 million; post-concussion syndrome occurs in up to 20%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.